Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro.
Article Details
- CitationCopy to clipboard
Wang Y, Fei D, Vanderlaan M, Song A
Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro.
Angiogenesis. 2004;7(4):335-45. doi: 10.1007/s10456-004-8272-2. Epub 2005 May 9.
- PubMed ID
- 15886877 [ View in PubMed]
- Abstract
Bevacizumab (Avastin, Genentech) is a humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF), a critical angiogenic factor involved in both physiological and pathological conditions. It has been recently approved by the US FDA as a first-line therapy for widespread metastatic colorectal cancer. This report is a detailed biological characterization of bevacizumab in a variety of in vitro models. It is shown that bevacizumab potently neutralizes VEGF and blocks its signal transduction through both the VEGFR-1 and VEGFR-2 receptors, as demonstrated by the inhibition of VEGF-induced cell proliferation, survival, permeability, nitric oxide production, as well as migration and tissue factor production. Although bevacizumab retains the ability to bind to human Fcgamma receptors and complement protein C1q, it does not demonstrate cell or complement-mediated cytotoxicity in either VEGF producing or targeting cells. Thus the mechanism of anti-tumor activity of bevacizumab is most likely due to its anti-angiogenesis effect through binding and neutralization of secreted VEGF.
DrugBank Data that Cites this Article
- Drug Targets
Drug Target Kind Organism Pharmacological Action Actions Bevacizumab Complement C1q subcomponent subunit A Protein Humans UnknownNot Available Details Bevacizumab Complement C1q subcomponent subunit B Protein Humans UnknownNot Available Details Bevacizumab Complement C1q subcomponent subunit C Protein Humans UnknownNot Available Details Bevacizumab High affinity immunoglobulin gamma Fc receptor I Protein Humans UnknownNot Available Details Bevacizumab Low affinity immunoglobulin gamma Fc region receptor II-a Protein Humans UnknownNot Available Details Bevacizumab Low affinity immunoglobulin gamma Fc region receptor II-b Protein Humans UnknownNot Available Details Bevacizumab Low affinity immunoglobulin gamma Fc region receptor II-c Protein Humans UnknownNot Available Details Bevacizumab Low affinity immunoglobulin gamma Fc region receptor III-A Protein Humans UnknownNot Available Details